Institutional investors purchased a net $213.1 thousand shares of SLXP during the quarter ended December 2012 and now own 97.55% of the total shares outstanding. This majority interest is a greater percentage than is typical for companies in the Pharmaceuticals: Other industry and highlights that the smart money sees this stock as an important holding.
| Other institutional | 48.84% |
| Mutual fund holders | 48.71% |
| Individual stakeholders | 13.41% |